healthday.com
Cure8 news brief
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
Medications
Mirikizumab
IL-23 inhibitor
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
This approval adds a newly authorized biologic option (mirikizumab/Omvoh) for adults with moderate-to-severe Crohn disease, including people who have not done well on steroids, immunomodulators, or prior biologics.
The drug’s reported one-year remission and healing results suggest it may help some patients achieve longer-term disease control.
Who Should Pay Attention
Adults with moderately to severely active Crohn disease; people who have had inadequate response or intolerance to corticosteroids, immunomodulators, or biologics; clinicians who treat IBD; researchers following new IBD therapies.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
FDA approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn disease based on phase 3 VIVID-1 results showing higher rates of clinical remission and endoscopic healing at one year versus placebo.
The drug targets the IL-23 p19 pathway and is noted as the first biologic for Crohn’s with disclosed two-year phase 3 efficacy data in over 15 years. Approval was granted to Eli Lilly.
Keep In Mind
The article summarizes a press release and FDA approval based on the phase 3 VIVID-1 trial; it reports one-year outcomes and mentions two-year data disclosure but does not provide full trial details here.
This is a regulatory approval announcement, not treatment guidance—discussions with a treating clinician are needed to understand if Omvoh is appropriate for an individual patient.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationhealthday.com
Indexed viaBing News
Source typeResearch news
PublishedJan 16, 2025, 3:08 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
A new FDA approval expands treatment options for adults with moderate-to-severe Crohn's disease and means mirikizumab (Omvoh) is now approved for both Crohn's disease and ulcerative colitis. The decision was based on...
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...